TMPRSS2 and prostate carcinoma: The quantitative assessment showed significantly reduced TMPRSS2 protein expression in prostate cancer patients receiving ADT compared to those not receiving ADT (mean histoscores: 152.7 vs. 225.0, p = 0.037) (Figure 2A–D).